EDNRA and B-cell chronic lymphocytic leukemia: The observed ability of ETAR selective antagonist to interfere with intrinsic and extrinsic growth/protective signals of CLL cells may be explored, both experimentally and clinically, as a possible novel therapeutic approach in CLL.